MYCN and cancer: This is typically the case for MYCN amplified (MNA) neuroblastoma, accounting for about 50% of the high-risk cases sharing a 50% 5-year survival rate [3].The driving role of MYCN in cancer was confirmed in genetically engineered mouse models [4–8].